Cannabis investors had already been shifting from “unproven potential” to “profitability” over the past several quarters prior to the global health crisis. With the COVID-19 outbreak, investors have fled previous investments to profitable companies that aren’t reliant on costly or dilutive funding to sustain their operations.

THC BioMed Intl Ltd. (CSE: THC) recently recorded its second consecutive quarter of profitability along with more than $1 million in revenue. This represents profits of $88,191 for the three months ended January 31, 2020. Investors looking for exposure to the cannabis industry may want to take a closer look at the stock as an alternative to companies with high cash burn rates and losses in operations.

Click Here To Receive Updates on THC BioMed

Growing Revenue & Outlook

THC BioMed generated more than $1 million in revenue during the first two quarters of fiscal year 2020 with an average selling price of $4.20 per gram to medical patients and recreational buyers, including the Ontario Cannabis Store and BCcannabisonline. During the second quarter alone, revenue rose 163% year-over-year to $1,246,625.

“Over the last year, we have completed and started using new grow rooms to increase our output,” said President & CEO John Miller. “Our focus on high-quality, indoor-grown cannabis at reasonable prices has made our cannabis a best seller.”

The company achieved several key operational milestones over the past six months:

Sales of THC Kiss began on April 10, 2020. The cannabis beverage can be purchased by THC BioMed’s medical patients via the company’s online store.
Pure Cannabis Sticks — or filtered, paper cylinder pre-rolls — went into automated production.
A new three-year lease was signed for a property adjacent to the company’s production facility, which will be used to free up space for more production.
Its Cannabis Act license was amended to include the production and sale of cannabis edibles, topicals and extracts, opening the door to new markets.

Management believes that these operational milestones pave the way for revenue growth over the coming quarters. In particular, the launch of Cannabis 3.0 products will expand the company’s addressable market, while the production efficiencies offered by Pure Cannabis Sticks boost bottom line performance.

Click Here To Receive Updates on THC BioMed

Sustainable Profitability

THC BioMed reported net income of $88,191, gross profit before fair value adjustments of $759,959, and adjusted EBITDA of $131,549 during the second quarter, representing its second consecutive quarter of profitability—a rarity among licensed producers that have historically experienced a high cash burn rate.

Second quarter net income was lower than the $688,925 reported during the first quarter on the surface, but gross profit before fair value adjustments and adjusted EBITDA were higher than first quarter levels of $295,480 and $890, respectively. These figures suggest that the actual bottom line performance has improved quarter over quarter.

“We are proud to have achieved our second consecutive profitable quarter,” added Mr. Miller. “Our financial statements for Q2 2020 reflect the improvements we have realized in all key indicators of economic progress.”

It’s worth noting that the average price of $4.20 per gram is lower than the average prices reported for other licensed producers, which makes the profitability even more significant, as margins are lower than the competition. If industry average prices trend lower, the company doesn’t have to cut its prices in order to remain competitive.

Looking Ahead

THC BioMed Intl Ltd. (CSE: THC) is one of the few profitable licensed producers in the industry, giving them an edge over other companies that are reliant on potentially dilutive future fundraising to stay alive.

Click Here To Receive Updates on THC BioMed

Click here to read the full feature: https://bit.ly/2V2r0Se

THC BioMed Contact:
CEO: John Miller
[email protected]
844-842-6337

CFN Media Contact:

President Frank Lane
[email protected]
206-369-7050

About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis, CBD & Psychedelic industries.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

What is the ideal setting for a brand to showcase its wares to the retail consumer? It is certainly not a crowded store with hundreds of brands competing for limited shelf space and consumer attention. Every brand out there would much rather have its own store, featuring its own product offerings, staffed by expert sales associates ready to educate consumers on the value of their products. In short, every brand would like its own version of the Apple Store or the Gap. Of course, every brand can’t afford to develop its own store, and cannabis licensing requirements often make the idea even more untenable.

CalEthos may have the answer for cannabis brands struggling to solve this problem. The company is currently financing the first of several planned cannabis superstores, appropriately called SHOWCASE, in Southern California. The concept is to provide partner cannabis brands their own space within a 20,000 sq. ft. SHOWCASE footprint, allowing them to fully display all that a brand has to offer. Each SHOWCASE location will also feature a medical pharmacy, an event center for community and consumer education, and a cafe and lounge areas to enhance the consumer experience and extend the shopper’s stay. Rather than the cramped, hurried environment common throughout retail cannabis, SHOWCASE promises to cater to both the customer and the brand in an elevated, inviting space.

CalEthos President Piers Cooper sat down with CFN Media to discuss the ideal setting for retailers to SHOWCASE their cannabis brand. Please click on the video below for the full story.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

Click below to hear CalEthos’ President Piers Cooper discuss the SHOWCASE concept

CalEthos Did the Homework

The two executives largely responsible for the CalEthos concept, CEO Michael Campbell and President Piers Cooper, have a long history in advising, building, and investing in companies both private and public. They kept bumping up against the emerging cannabis industry and decided to investigate, looking for opportunities arising from shortcomings in the young marketplace. They settled on retail, visiting a wide variety of stores and brands and talking to everyone involved, from the consumer to the staff to the product companies.

These investigations highlighted the problems listed above, both for the brand and for the consumer. Cannabis has been legalized, but many stores still carry a bit of a black-market vibe which is uninviting to newer cannabis consumers. Space is at a premium, as most dispensaries don’t have the capital to build large format stores or expand and upgrade existing stores. Budtenders are generally helpful, but they are usually limited to some personal advice about a brand they like before making the sale and moving on to the next in line.

Click Here to Receive a CalEthos Investor Presentation & Company Updates

From the brand side, it is almost impossible to build a loyal customer base under such conditions. With advertising options limited, brands don’t have anywhere to turn. A given dispensary may carry 5 out of the brand’s 50 SKUs, whilst those 5 products are generally displayed amongst many other brands with limited space or capability for differentiation.

Campbell and Cooper came away from their research knowing there had to be a solution that provided a better consumer experience while enabling product makers to actively engage and educate those consumers.

Click below to hear CalEthos’ President Piers Cooper discuss The SHOWCASE Model Inspiration

The SHOWCASE Solution

CalEthos enlisted the help of Stephen Brady, the man responsible for the design of numerous Ralph Lauren, Bloomingdales, Gap, Old Navy, Banana Republic and other retail stores. Brady helped them realize the vision of an open, engaging, vital retail setting in which consumers are given space and options and educational opportunities. CalEthos is tuned in to the need to invite and educate ‘canna-curious’ consumers, and the SHOWCASE design enables that with event and education space along with lounge areas and a cafe. The concept is not turn and burn, though there is nothing stopping a customer from grabbing what they need and leaving quickly. Rather, the concept is explore and learn and enjoy. CalEthos believes consumers will gravitate to its model over the typical marijuana dispensary in the Southern California market.

Rendering of CalEthos SHOWCASE retail store

The company already knows that brands will appreciate the opportunity to create their own stores-within-a-store. Brand partners can procure dedicated space under the SHOWCASE Brand Membership Program that ranges from a 10’ x 16’ boutique with 90’ of shelf space, to shared kiosks in specialty product sections with 21’ of shelf space per brand, to 18’ of refrigerated shelf space in the Chill Zone for edibles and beverages. The SHOWCASE design also features a pharmacy dedicated to medicinal cannabis products and to provide advice for consumers exploring alternative medical options offered by cannabis products. All spaces are staffed by associates who are highly trained on products sold in their display areas.

Ready to SHOWCASE your Brand? Click Here to Apply.

Click below to hear CalEthos’ President Piers Cooper discuss the CalEthos Event Center

Overall, the concept is compelling and a refreshing change from the typical dispensary environment. Southern California, with its advanced legal market, huge population, and trend-setting reputation, is a prime location for the SHOWCASE concept. Investors interested in learning more about the opportunity are encouraged to follow the links. The future of cannabis retail awaits.

For Additional Information on CalEthos Please Visit the website at: https://www.calethos.com

CalEthos

CEO Michael Campbell

[email protected]

714-352-5315

CFN Enterprises

President Frank Lane

206-369-7050

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Robin Lefferts

Psychedelics are rapidly becoming both a mainstream treatment option and investment opportunity. With growing interest among researchers, forward-thinking companies are starting to build a presence in the space. 

In this article, we will take a look at the growing body of therapeutic evidence for psychedelics. How decriminalization is gaining ground, and how Ehave Inc. (OTC: EHVVF) along with other public companies are positioning themselves in the psychedelic space.

A Growing Body of Evidence

A growing body of evidence supports the use of psychedelics to treat a variety of different medical conditions. In 2016, Johns Hopkins researchers found that psilocybin produced a substantial and sustained decrease in depression and anxiety in cancer patients. A follow-up study on the same patients five years later found lasting effects from the one-time therapy.

The therapeutic evidence has become so overwhelming that Johns Hopkins established the Center for Psychedelic and Consciousness Research earlier this year to start rigorously investigating the drugs’ therapeutic potential. Researchers believe that it could have a beneficial impact on everything from smoking addiction to Alzheimer’s disease.

In addition to medical benefits, there’s plenty of anecdotal evidence that microdoses of psychedelics could improve mental health, well-being and productivity. Many prominent business leaders in Silicon Valley, including the late Steve Jobs, praised the benefits of microdosing psychedelics for creativity and cognition.

Click here to receive Ehave News and Investor Updates

Decriminalization Gain Ground

The growing interest among researchers has bolstered attempts by activists to decriminalize psychedelics throughout the country. Denver, Oakland and Santa Cruz have already decriminalized psychedelics over the past year, while California, Oregon and Iowa could see psychedelic-related measures on the ballot in November.

In the nation’s capital, Rep. Alexandria Ocasio-Cortez, D-NY recently introduced legislation that would allow researchers to more easily study the therapeutic and medicinal benefits of psilocybin and other psychedelics. These developments mirror what happened in the early medical cannabis industry where regulations were slowly relaxed over time.

It’s worth noting that these early efforts seek to decriminalize psychedelics and pave the way for research. Unlike the cannabis industry, there’s less interest in a recreational market and more interest in building a viable alternative therapy for countless different medical conditions that impact the brain—many without any current options.

Investors Start Taking Notice

Mind Medicine Inc. (NEO: MMED), better known as MindMed, became the first psychedelic pharmaceutical company to go public earlier this year on the NEO exchange. After raising $24.2 million in pre-public funding, the company plans to initially focus on addressing the opioid crisis and other forms of addiction with the use of psychedelics.

Click here to receive Ehave News and Investor Updates

Ehave Inc. (OTC: EHVVF) is another publicly-traded company in the space. Its Mycotopia Therapy subsidiary recently acquired PsychedeliTech and plans on hosting an inaugural PsyTech Summit in Tel Aviv, Israel on June 14-15, 2020. The conference will be modeled after the highly-successful CannaTech conference and connect key industry participants.

The company believes that it’s Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world’s strictest privacy laws. It’s an optimal way to compile psychedelic research and results to provide easy access for scientists globally.

Looking Ahead

Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Cannabis investors may want to consider building a position in some of these companies given the similarities.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic active ingredient in some types of mushrooms, as well as other psychedelics like LSD, as the next big natural drug discovery. Researchers are in various stages of studying the effect of psychedelics on conditions ranging from depression to addiction to migraines to anxiety and more. It might be time to pay attention to the field as more researchers test the therapeutic potential of psychedelics.

One company certainly paying attention is EHave, Inc. (OTC: EHVVF). The company has developed a technology platform that helps doctors and patients make data-informed treatment decisions for a variety of mental health indications. With the formation of a subsidiary called Mycotopia Therapy and an initial acquisition of PsychedeliTech, the company is becoming a major player in the emerging psychedelic medicine space. The Ehave Dash, already HIPAA and GDPR compliant, will be used as a central clearinghouse for psychedelic research data and clinical trial tracking with the intent to further advance the science of psychedelic therapies.

Psychedelic Research Enters the Mainstream

Just last year, the Johns Hopkins School of Medicine opened the Center for Psychedelic and Consciousness Research in Baltimore. Headed by renowned researcher Roland R. Griffiths, Ph.D., the Center aims to further research the school has already been conducting. Initial areas of focus include potential therapies for opioid addiction, Alzheimer’s disease, PTSD, and anorexia among other conditions. Johns Hopkins researchers have been pioneers in the field as the first researchers, in 2000, to get US regulatory approval for the use of psychedelics in health volunteers. Since then, the school’s researchers have published more than 60 peer-reviewed studies and demonstrated safe practices for psychedelic research that have set the standard for other studies across the world.

There are plenty of other researchers pursuing potential psychedelic therapies. The University of Toronto Mississauga recently started a Psychedelic Studies Research Program. The British Columbia Centre on Substance Abuse is launching a Phase III clinical trial of MDMA as a treatment for PTSD, in conjunction with 16 other locations throughout North America and Israel, and funded by the nonprofit Multidisciplinary Association for Psychedelic Studies (MAPS). The MAPS site has comprehensive lists of research, both ongoing and completed, conducted by MAPS as well as other organizations. There is a lot of scientific interest in psychedelics, and it is growing exponentially.

EHave’s Plan

The PsychedeliTech acquisition is just the first step for EHave in a comprehensive plan to bring together the diverse and scattered research (and researchers) into one collaborative platform. PsychedeliTech is hosting the inaugural PsyTech Summit March 29-30, in Tel Aviv, Israel. Modeled after the hugely successful CannaTech conference, a global gathering for the cannabis industry. In fact, PsychedeliTech is a subsidiary of Israel Cannabis Limited (iCAN), the creator of the CannaTech conference, and the two conferences run back-to-back at the same location this year. 

The goal of the PsyTech Summit is to elevate the psychedelics conversation, foster normalization, and accelerate innovation. Why is EHave acquiring the company and the conference? Because its subsidiary, Mycotopia Therapy, was founded to work toward the same goals. EHave believes its EHave Dash platform can play a crucial role in the worldwide advancement of psychedelic research. The Dash is HIPAA and GDPR compliant, meaning that the data carried by the Dash is totally secure and in line with the world’s most strict privacy and security rules. The idea is to compile all psychedelic research and results in the EHave Dash, providing valuable and easily accessible information for scientists across the globe as they pursue their own studies.

The PsyTech Summit is a perfect vehicle for fostering crucial relationships with innovators in the space. It could also serve to introduce Mycotopia Therapy to other potential investments or acquisitions that fit under the company’s mission, as the PsyTech acquisition is just the first of many moves to come.

The Upshot

The story of psychedelics as therapeutic treatments is now unfolding across the world. There is a lot of promising research into a wide variety of problematic neurological and psychological conditions that have resisted more traditional treatments to date. It’s a potentially explosive industry in its infancy, and EHave is making moves to become a key cog in the industry’s development. Keep an eye out here for more news regarding both the company and the movement in general.

Please click here for additional Information on EHave, Inc. (OTC: EHVVF)

Please click here for additional Information on Mycotopia Therapy

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now President and CEO of Isracann Biosciences (CSE: IPOT) (OTCPK: ISCNF), Israel’s first pure-play cannabis company to be listed in Canada and the U.S.

“We started looking for other jurisdictions that were similar to Canada four or five years ago and Israel is a prime candidate,” Jones told CFN Media in a recent interview. 

While Israel indeed is following in the footsteps of Canada in many ways, it arguably has the richest history of cannabis research in the world, which provides a nice backstop when it comes to regulations, education and infrastructure. Add in nearly perfect climate for growing cannabis and new cannabis export laws and Isracann setting up headquarters in Israel is one savvy move.

Click Here To Receive Isracann’s Investor Presentation

Jones, whose background is in the capital markets, is looking for his next success after taking cannabis/hemp pet product company True Leaf Medicine public in 2014 at a $10 million valuation and exiting just two years later at a $150 million valuation.

First Crop in June 2020

Isracann is fully funded to construct a 230,000 square-foot facility in Nil, a moshav in southern Israel. The company recently received facility design and land use approvals from the Israeli Land Authority and is soon expecting the final permits for initiate groundbreaking on the first phase of the project.

Phase 1 will include building two 57,500 square-foot hybrid greenhouses and a packing facility with a 6,500 square-foot post-harvesting area, office space and kitchen for employees.

Isracann, which has retained top firms in the Israeli cannabis industry to oversee the design and construction of the cutting edge facility, expects the build to be complete in six months. “We’re roughly timing June 2020 as first crop,” said Jones.

Inexpensive (Really Inexpensive) Production Costs

Once the plants are harvested and dried, they will go on to Isracann’s in-country manufacturing partner to be turned into any number of products for the expanding domestic Israeli market. Israel has one of the highest per capita usage rates of medical cannabis in the world. 

Furthermore, the company intends to capitalize on the fact that Israel this year passed legislation permitting medical marijuana exports, making it only the third country to do so (Canada and Netherlands). Expectations are for the regulatory framework to be in place for exports from Israel to commence in mid-2020.

That’s good timing for Isracann considering when it is expecting its first crops.

Isracann is estimating the cost of production to be just C$0.40-C$0.60 per gram. To give that a little perspective, consider that production costs for cannabis producers in Canada are typically in the range of C$1-C$3 or higher per gram.

Click Here To Receive Isracann’s Investor Presentation

That’s the type of huge opex difference that can give Isracanna the ability to keep strong margins in the domestic market and a competitive advantage when it looks to the future and the  massive European markets that are home to over 750 million people.

Isracann already has a distribution partner for penetrating the European markets when that time comes. The first country on tap is Germany, the largest economy in the E.U. and a burgeoning medical cannabis market.

“Made in Israel”

When it comes to cannabis, Israel is a name recognized globally for its R&D, venerable scientists and agriculture and high quality. To that point, it works as a branding badge for Isracann because distributors and retailers understand that cannabis from Israel is held to a high standard. 

In keeping with those standards, Isracann’s facilities will carry important accreditations, including Israeli Medical Cannabis Good Agricultural Practices (IMC-GAP), Israeli Medical Cannabis Good Security Practices (IMC-GSP) and European Union Good Manufacturing Practices (EU-GMP) certifications.

Speaking to that, Jones said, “[Israel] has 50+ years of cannabis research and they’re really starting to break open the doors on novel products and new formulations; We’re obviously very excited about that.”

Stay tuned for Part 2 of Isracann’s CEO Darrryl Jones exclusive video interview series.

Click Here To Receive Isracann’s Investor Presentation

To learn more about Isracann Biosciences Click Here

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Vocal cannabis activist Snoop Dogg has signed on as a brand ambassador for Israeli start-up Seedo (OTC: SEDO), the maker of a refrigerator-type of a machine for auto-growing plants, including cannabis. The indelible award-winning rapper says he’s “all the way down with” the Seedo Homelab and the utility it brings to allow people to grow their own plants in unused space at home.

With the help of Snoop, Seedo is one of a handful of companies making news that complements the storied history of cannabis in Israel that includes the discovery of cannabinoids decades ago and the passage of legislation this year that makes the country one of only of a small group in the world allowed to export cannabis.

Another company etching its name in Israeli cannabis business is Isracann Biosciences (CSE: IPOT) (OTC: ATLED), the first pure-play cannabis firm in the country to list in Canada.

Technology in Israel

Seedo’s smell-proof, self-contained cultivation box lets users with no previous agriculture experience produce “brag worthy yields” with little more effort than planting a seed and monitoring the process through an app. The world’s first fully automated and controlled indoor growing machine drums up memories of the old hands-off, “set it and forget it” Ronco rotisserie.

Snoop Dogg, whose real name is Calvin Cordozar Broadus Jr., will partner with Seedo on a variety of initiatives generating awareness of the innovative technology and the environmental benefits and social opportunity affiliated with it.

On a larger scale, Isracann is developing commercial-scale cultivation capacity and finding strong investors support to execute on the model, as indicated by a recent C$10.1 million financing round. The money is earmarked in part to build-out 230,000 square feet of the company’s phase 1 facility. The initial phase will have capacity of 23,500 kilograms of cannabis per annum.

Click Here To Receive Isracann’s Investor Presentation

Benefiting from the latest hybrid greenhouse technology and the near-perfect weather conditions in Israel for growing cannabis, management estimates that it will be able to produce its high-quality cannabis for as little as 40 cents per gram, a favorable production price for premium product. 

Everything Coming Together 

Isracann said on Monday that its current cash position allows for accelerating Phase 1 of the construction program, which includes: 

•     finalization of greenhouse facility design for cannabis cultivation and production; 
•     rapidly advancing greenhouse and related facility construction; 
•     ensuring adequate controls are in place against any diversion, theft and loss of cannabis products; and
•     ensuring compliance with other protective security, health, and safety requirements in accordance with Israeli regulations 

As milestones with the production facility draw nearer, Isracann has already entered into agreements for medical cannabis cultivation projects in Israel with local licensed stakeholders. 

The anonymous stakeholder is shouldering part of the responsibility of the construction of the Isracann greenhouses, as well as bearing the cost of electricity, licenses, and property and related land taxes for the large cultivation and processing facility.

Click Here To Receive Isracann’s Investor Presentation

Piquing interest that there are more positive developments on the horizon, Isracann CEO Darryl Jones said on Monday, “We have lined up several key organizations and personnel and look forward to announcing a number of these key commercial agreements in the days and weeks ahead.”

Beyond addressing the underserved domestic market, Isracann has established distribution resources to leverage the export-friendly Israeli laws to send its future cannabis goods into the massive European markets.

Team Gets Stronger with Deepened Roots is Israel

Isracann’s leadership includes the likes of Nitin Kaushal (managing director with PwC), Brett Allan (founding member The Green Organic Dutchman (TSX: TGOD), VP Corporate Development Organigram (TSX: OGI)(NASDAQ: OGI) and Justin Cooper (co-owner of Green Planet, the largest privately-owned hydroponics chain in Canada).

Click Here To Receive Isracann’s Investor Presentation

Now, the company has added Dr. Irit Arbel to its Board of Directors. Dr. Arbel has decades of multi-disciplinary biopharma, technology and governance experience. A serial entrepreneur, she has founded, held C-suite positions and other senior roles at companies such as Brainstorm Cell Therapeutics (NASDAQ: BCLI), Pluristem Life Sciences (NASDAQ: PSTI), Neurocords, Ltd., Savicell Diagnostics and RFB Investment House.

There is certainly an Israeli connection here with Dr. Arbel. She was previously an Israeli Sales Manager for the pharma Merck, Sharp & Dohme. She also holds a Chemical Engineering degree from the Technion, Israel’s Institute of Technology.

To learn more about Isracann Biosciences Click Here

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

RYAH Finds Top Priority is Treating Mental Health, Over 28,000 Women Surveyed

New York, NY, October 30, 2019 – RYAH Medtech, Inc. (“RYAH” or the “Company”), a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry, has released a data analytics report on women and their medical use of cannabis. Surveying feedback from 28,211 women, the report found that the average female patient prefers strains that are high in CBD, THC, and well-balanced strains to help treat mental health conditions.

“The female patient demographic has not received enough industry attention or study up to this point. Making up more than 45% of the patient pool, it’s our responsibility to better understand what this demographic looks like, which medical issues they are seeking treatment for and what treatments are providing successful outcomes. Women are turning to medical cannabis to treat their mental health concerns and it’s a valuable insight for care providers that we have learned strains high in CBD are helping them gain relief,” said Gregory Wagner, Chief Executive Officer of RYAH.

The data, taken from RYAH’s propriety data pool, and related insights, examine female medical cannabis patient demographics and how women utilize different strains of medical cannabis. The report found that women are a growing segment of the medical cannabis market, comprising 45.1% of the patient population currently using RYAH’s Data Platform. The average female patient prefers strains that are high in CBD, THC and well-balanced strains. They also prefer Indica and Sativa strains equally. Mirroring the common ailments most treated by men, women are seeking medical cannabis for anxiety, depression, stress and pain relief.

In comparing the current data with data in two other reports on women and cannabis, RYAH’s data mirrored and confirmed that women are more likely than men to use cannabis for the specific treatment of fibromyalgia, nausea, anorexia, irritable bowel syndrome and migraines. These reports also indicated that women started to use medical cannabis later in life than men, typically after 30 years of age.

The report also went into some of the specific strains that women prefer for their treatment. Women prefer Cannatonic (7-15% THC, 12% CBD Indica-dominant), Harlequin, Super Lemon Haze (>22% THC, <1% CBD, Sativa-dominant), and Purple Candy for the treatment of anxiety. They preferred AD/CA (>1% THC, 20% CBD, Indica-dominant), Gorilla Glue, Harlequin, and Purple Candy for the treatment of fibromyalgia.

“Medical cannabis has the ability to change lives for the better and we are hopeful the insights from our data pool and related analysis can improve patient outcomes and inspire further study,” added Wagner.

The full report and related insights are available online at: https://us.ryah.com/wp-content/uploads/2019/10/RYAH-OCTOBER-REPORT-.pdf

About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for growers, dispensaries and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.

Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” and similar expressions as they relate to the Company; execution of additional distribution agreements; and the results users may receive from using RYAH are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. These factors include, without limitation: the general business and economic conditions in the regions in which the Company operates; the ability of the Company to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on the Company’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which the Company is exposed; the failure of third parties to comply with their obligations to the Company or its affiliates; the impact of new and changes to, or application of, current laws and regulations; a novel business model; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by the Company; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and the risk associated with a business in the cannabis industry. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Thursday, October 17, 2019 marked a milestone moment for the world of legal recreational cannabis with new product forms like concentrates, extracts, vaporizers and edibles becoming legal in Canada. This second phase of legalization comes only one-year after Canada’s federal legalization of recreational adult-use cannabis. 

In the inaugural episode of a new cannabis podcast called “Session Garden” hosted by John Fowler, Chief Advocacy Officer at The Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF), an esteemed panel tackles the opportunities and obstacles associated with Cannabis 2.0, the colloquial name given to the new Canadian cannabis regulations that just came into effect on October 17th. 

John Fowler Chief Advocacy Officer of The Supreme Cannabis Company

John Fowler is a well-recognized name in the cannabis industry, serving as an advocate, activist and entrepreneur, including founding Supreme Cannabis. Supreme Cannabis is a TSX (FIRE) and OTCQX (SPRWF) listed company, it is the holding company for a leading diversified portfolio of premium cannabis brands, products and facilities. Now, the company and John launch Session Garden to address, as John puts is, “a lack of hard-hitting and insightful content focused on all aspects of the cannabis community.”.

Click here to receive an investor deck and corporate updates

In the first episode, Fowler sits down with Brigitte Simons, Chief Scientific Officer at Pasha Brands, Brad Poulos, a professor of cannabis entrepreneurship at Ryerson University, and Talaal Rshaidat, Chief Scientific Officer at humble+fume, to take a deep dive into the direction of the cannabis market, challenges facing the industry and who will be winners with Cannabis 2.0.

Cumulatively, the panel has a highly relevant and diversified background in cannabis, ranging from technology to brand and product development.

The 2.0 Groundwork

When Canadian legislatures legalized adult-use cannabis on October 17, 2018, they didn’t have any true references to use for guidelines. As such, they didn’t jump in with both feet by any stretch of the imagination, only permitting the sale of cannabis flower and oil. Cannabis 2.0 will introduce new products and market segments, including concentrates (which serve as the basis for vape pens), topicals and ingestible products, such as drinks and edibles. As noted by Ms. Simons, there will also be an insurgence of other items, such as bath and luxury beauty care and wellness products.

Pasha is eager to re-innovate baked goods and specialty products, such as those catering to healthier lifestyles, including plant-based products that will eliminate usage of preservatives and high fructose corn syrup.

Shy of some Health Canada restrictions on edible products, Rshaidat describes the opportunity to introduce new products as “free reign.”

“The consumer is waiting,” said Simons. “They’ve proved to us before in those type of sales that the consumer is ready for that,” she added.

 Click the photo above to listen to Supreme Cannabis’ John Fowler’s Podcast “Session Garden”

Cannabis 2.0 Shakes Up Everything…Are You Ready?

Deloitte estimates that the new products coming to market in Canada will add another $3.0 billion to the industry size on top of sales of flowers and oils. So what will be the dominant market segment? 

On this point, the panel sparks up a conversation on how different types of cannabis consumers will likely lean towards different product forms. The panel digs deeper into the topic of 2.0 products, touching on the impact of simply adding cannabinoids to existing products versus innovating new ones.

Click here to receive an investor deck and corporate updates

The panel agrees that innovation and thoughtfulness in product development are going to be integral to the success of 2.0 products. For example, while the emphasis right now is largely on the popular cannabinoids CBD and THC, the panel discusses the opportunities ahead with innovation that will recognize and tap into the more than 100 other known cannabinoids. When contemplating about the market and where it can go, this sort of thinking speaks plainly to how early we still are in product development and the significant potential that lies ahead.  

Educating the Public

On the podcast, the group discusses one of the greatest challenges to manufacturers, with limited tools to reach consumers, it is difficult to educate consumers on the full arc of cannabis consumption. Science plays a tremendous role in the user experience and that can be difficult to convey. Things such as pharmacokinetics and bioavailability can vary greatly between strains and product forms. When advertising is negligible and communications are restricted, how can companies educate consumers? Fowler and his guests dive deep into this topic and discuss the varying information needs of different consumers, explaining why education is more important now than ever.

Click here to receive an investor deck and corporate updates

So Who Wins?

Simply, companies that have the foresight and solutions to overcome the aforementioned challenges detailed by Fowler, Simons, Poulos and Rshaidat. An overarching takeaway is that there are tremendous growth opportunities for ancillary companies to fill gaps in the value chain.

There is also something to be said about being forward-thinking towards Cannabis 3.0. All the panelists are in the position they are because they made prescient decisions to be prepared for Cannabis 2.0 and now they’re looking for what’s next. 

Insightful and entertaining, but most importantly, informative, John Fowler’s Session Garden should become required listening for all in the cannabis space. We are already looking forward to episode two, set to air this Thursday October 31st. 

Click here to receive an investor deck and corporate updates

 For additional information, visit the company’s website at: https://www.supreme.ca/about-supreme-cannabis

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ash Stringer

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as “expects”, “will”, “anticipates”, and “estimates”; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief “snapshot” of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled “Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

As the nascent European legal cannabis market emerges, Canadian companies that have cut their teeth in their home markets are taking that experience overseas to capitalize on a much larger market opportunity. The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) is a model of how to build a successful cannabis portfolio at a blistering pace. And the way that they just made their move into Europe was savvy, to say the least. 

Here’s why…

There are about 37 million people in Canada. There are over 513 million people in the European Union, of which around 480 million citizens have access to medical cannabis in some way, shape or form. Of the 28 members of the E.U. (including the U.K. at this point), only Bulgaria, Hungary, Latvia, Slovakia and Sweden are still steadfast on cannabis being illegal in all forms, including cannabis-based drug derivatives.

 Legal Cannabis In Europe

Canada is undoubtedly a global leader, cementing its position in history last year as the first industrialized country – and second country ever behind Uruguay – to legalize recreational marijuana for adults. The setting of the framework was invaluable to pioneering cannabis companies and management. When the dust settles in the future, the sheer volume of potential patients (>12x more) suggests that the European markets will be much larger than that of Canada, providing a once-in-a-lifetime opportunity to put that experience to use.

Click here to receive an investor deck and corporate updates

Like everything else cannabis, just how big the market will be is subjective, but it will be huge regardless of guesstimate. For example, in its ‘The European Cannabis Report,’ Prohibition Partners said earlier this year that it sees Europe as the world’s biggest legal cannabis market in the next five years and reaching up to €123 billion (US$136.7 billion) by 2028.

Executional Excellence: This is How You Do It

In about three years, Supreme Cannabis has built and scaled its cannabis business in Canada, while more recently stepping into global markets through deals in Malta and Lesotho.

The Supreme portfolio currently consists of six subsidiaries, covering a swath of the cannabis industry, including IP discovery, cultivation, production (of multiple goods) and sales into eight Canadian provinces. Some of this has been organic growth, while some, such as the recent acquisitions of Truverra and Blissco, has been inorganic. The flagship brand in the family is 7ACRES, which expanded its cultivation capacity in just 12 months from 3,000 square feet to 230,000 square feet for production capacity of 33,580 kilograms.

Supreme Cannabis Company Chief Advocacy Officer and Founder John Fowler

Nothing speaks more clearly to the ability to scale than Supreme this month providing revenue guidance for the next year in the range of $150 million to $180 million. If it makes good on this guidance, Supreme will have become one of the top cannabis companies in the world based upon annual revenue in less than five years.

Click here to receive an investor deck and corporate updates

The robust growth is owed to management’s ability to make prescient moves to stay in front of regulation changes in addition to operational excellence. This includes not only the recreational cannabis market as it stands today, but also the upcoming new laws in Canada anticipated for October.

The upcoming changes include cannabis extracts becoming available to Canadians. To position for market share, Supreme has partnered with PAX Labs, the top-selling pen-and-pod system in the U.S., for new premium pods for sale with the PAX Era systems in Canada. Supreme has also partnered with Wiz Khalifa’s Khalifa Kush Enterprises Canada to bring the popular U.S. brand to Canadians.

Khalifa Kush Enterprise Products 

Overseas, Supreme leadership made the prescient decision to strike a supply agreement and to invest $10 million in Medigrow Lesotho, a leading licensed medical cannabis oil producer in the Kingdom of Lesotho. Lesotho is a land-locked country surrounded entirely by South Africa, a country of 57 million that changed its laws in May to allow for legal sales of CBD (cannabidiol) products. 

Reaching Supreme Heights

Looking ahead to the burgeoning European cannabis markets, Supreme in June launched Supreme Heights, a London, England-based investment platform focused on CBD opportunities throughout Europe. The astute launch brought the company’s leadership, extensive comprehension of regulations, premium product commercialization, supply chains, marketing, capital markets and corporate support services to promising European upstarts who are seeking capital.

Click here to receive an investor deck and corporate updates

Patrick Morton, co-founder of Cannabis Invest UK, the leading cannabis investor conference in the country, has assumed the role of CEO of Supreme Heights with key members of existing Supreme Cannabis leadership joining the team. Morton has spent years developing an expansive network of local and global cannabis and CBD companies. 

 Click the photo above to receive additional information on Supreme Heights

Getting Morton involved once again points to the savvy decision making of Supreme. In one fell swoop, Supreme Cannabis has gotten unfettered access to Morton’s network, effectively giving it the opportunity to begin culling European companies for potential investments.

Oozing with Business Acumen

The relationship is bi-lateral for Supreme Cannabis. The obvious is investment arm and ROI that can result in high-margin revenue for the parent company by putting out its capital and lending some developmental and operational advice.

A second aspect was hit on by Morton when he said, “With guidance from Supreme Cannabis, we intend to make targeted investments in wellness brands that provide exposure to value-add categories in the UK and Europe’s CBD market, including vaporizers, edibles and beverages, topicals and ancillary services.”

CBD Products  

On the surface, this can be taken just literally because Supreme has experience in all these facets of the business. A read between the lines signals that Supreme indeed intends to make investments in European companies, as well as using the relationships as inroads to more business to further support the top and bottom lines.  

This is further understood with some “big picture” vision aggregating moves Supreme has made in the recent past. The acquisition of Truverra came with the company’s European subsidiary, Netherlands-based Truverra (Europe) B.V., which already has small-scale sales of its eponymous hemp-derived CBD products through its established distribution channels in the U.K. and Netherlands.

Don’t forget that Medigrow Lesotho, which already has over 400 employees, is building a facility expected to be an EU-compliant GMP facility for exports of CBD oils. Blissco’s current facility was also built to be EU-compliant GMP and will be capable of producing over 7 million bottles of tinctures in the next few months.

Against this backdrop, it is Navdeep Dhaliwal, CEO of Supreme Cannabis, probably said it most concisely with, “We look forward to driving value for Supreme Cannabis shareholders through this investment platform.”

Given the way Supreme took Canada by storm, it shouldn’t come as any surprise that they will take an equally aggressive approach to tackle the much bigger European markets.

Click here to receive an investor deck and corporate updates

 For additional information, visit the company’s website at: https://www.supreme.ca/about-supreme-cannabis

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.